Author

Ulrike Regina Schmits

Johannes Gutenberg University Mainz

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Hakim EchchannaouiiD· 2 shared Matthias TheobaldiD· 2 shared Alexander Schäffer· 1 shared Alexandra Reinbrecht· 1 shared Angelique Schönefeld· 1 shared Ashley WesterbackiD· 1 shared Borhane GuezgueziD· 1 shared Catherine WölfeliD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Hakim EchchannaouiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintOct 8, 2026

A signaling-optimized TIGIT chimeric switch receptor promotes metabolic fitness and antitumor efficacy of TCR/CAR T cells

Edite Antunes Ferreira, Kevin Jan Legscha, Ulrike Regina Schmits…·Hakim Echchannaoui

This paper introduces a fine-tuned chimeric switch receptor (CSR) that enhances TCR/CAR T cell metabolic fitness and antitumor efficacy by optimizing signaling from the TIGIT domain.

DOI 10.64898/2026.10.02.755760

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintDec 11, 2024

DNMT/G9a Complex Inhibition Uncovers Epigenetic Vulnerabilities and Induces IFN-Response in Acute Myeloid Leukemia

Angelique Schönefeld, Costanza Zanetti, Eric C. Schmitt…·Borhane Guezguez

This study shows that inhibiting the DNMT/G9a complex targets specific epigenetic vulnerabilities in AML, inducing an IFN response and improving therapeutic outcomes.

1 citation

humanDNA methylation

𝕏 PostBluesky